Journal of the American College of Cardiology
Original Investigation
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
Michael R. Zile, Brian L. Claggett, Margaret F. Prescott, John J.V. McMurray, Milton Packer, Jean L. Rouleau, Karl Swedberg, Akshay S. Desai, Jianjian Gong, Victor C. Shi and Scott D. Solomon
Table 3
Table 3
Change in NT-proBNP From Baseline (V2/V2a) to 1 Month After Randomization (V7): Categorical Analysis
Change in NT-proBNP at 1 Month | All Patients (N = 1,942) | Sacubitril/Valsartan (n = 971) | Enalapril (n = 971) | Between Treatments | ||
---|---|---|---|---|---|---|
OR† | 95% CI | p Value | ||||
Among patients with NT-proBNP >1,000 pg/ml at baseline | (N = 1,206) | (n = 612) | (n = 594) | |||
High-High∗ | 918 (76.1) | 425 (69.4) | 493 (83.0) | |||
High-Low | 288 (23.9) | 187 (30.6) | 101 (17.0) | 2.15 | 1.63–2.83 | <0.001 |
Among patients with NT-proBNP ≤ 1,000 pg/ml at baseline | (N = 736) | (n = 359) | (n = 377) | |||
Low-High | 124 (16.8) | 38 (10.6) | 86 (22.8) | |||
Low-Low | 612 (83.2) | 321 (89.4) | 291 (77.2) | 2.5 | 1.62–3.88 | <0.001 |
Values are n (%).
NT-proBNP = N-terminal pro–B-type natriuretic peptide; OR = odds ratio.
↵∗ High = NT-proBNP > 1,000 pg/ml; Low = NT-proBNP ≤1,000 pg/ml.
↵† OR for patients in the High-High group having a reduction of NT-proBNP that converted them to the High-Low group was twice as likely in those treated with sacubitril/valsartan versus those treated with enalapril (OR: 2.15); the OR of patients in the Low-Low group maintaining this low value of NT-proBNP and remaining in the Low-Low group was twice as likely in those treated with sacubitril/valsartan versus those treated with enalapril (OR: 2.50).
Advertisement